Deciphering the MHC-associated peptidome: a review of naturally processed ligand data

ABSTRACT Introduction: The availability of big data sets (‘OMICS’) has greatly impacted fundamental and translational science. High-throughput analysis of HLA class I and II associated peptidomes by mass spectrometry (MS) has generated large datasets, with the last decade witnessing tremendous growth in the breadth and number of studies. Areas covered: For this, we first analyzed naturally processed peptide (NP) data captured within the IEDB to survey and characterize the current state of NP data. We next asked to what extent the NP data overlap with existing T cell epitope and MHC binding data. Expert commentary: The current collection of NP data represents a large and diverse set of class I/II peptides mostly derived from self-antigens. These data overlap only marginally with existing immunogenicity and binding data and it is thus difficult to ascertain the correspondence between the different assay methodologies. This highlights a need for unbiased studies benchmarking in model antigen systems how well MHC binding and NP data predicts immunogenicity. Going forward, efforts at generating an integrated process for capturing all NP, curating associated metadata and accessing NP data from an immunological viewpoint will be important for development of novel methods for identifying optimal target antigens and for class I and II epitope prediction.

[1]  Bjoern Peters,et al.  The Immune Epitope Database: How Data Are Entered and Retrieved , 2017, Journal of immunology research.

[2]  Bjoern Peters,et al.  The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design , 2017, Front. Immunol..

[3]  S. Lemieux,et al.  MHC class I-associated peptides derive from selective regions of the human genome. , 2016, The Journal of clinical investigation.

[4]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[5]  Etienne Caron,et al.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.

[6]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[7]  Ruedi Aebersold,et al.  Analysis of MHC immunopeptidomes using mass , 2015 .

[8]  Philip R. Johnson,et al.  Accelerating Next-Generation Vaccine Development for Global Disease Prevention , 2013, Science.

[9]  J. Leunissen,et al.  The Human Leukocyte Antigen–presented Ligandome of B Lymphocytes* , 2013, Molecular & Cellular Proteomics.

[10]  Ilan Beer,et al.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.

[11]  P. Lackner,et al.  Naturally processed T cell-activating peptides of the major birch pollen allergen. , 2010, The Journal of allergy and clinical immunology.

[12]  Bjoern Peters,et al.  Naive Precursor Frequencies and MHC Binding Rather Than the Degree of Epitope Diversity Shape CD8+ T Cell Immunodominance1 , 2008, The Journal of Immunology.

[13]  A. Louise,et al.  Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers1 , 2008, The Journal of Immunology.

[14]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[15]  J. Yewdell,et al.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.

[16]  Eric W. Deutsch,et al.  The PeptideAtlas project , 2005, Nucleic Acids Res..

[17]  Steve Wilson,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[18]  Sorin Istrail,et al.  Comparative immunopeptidomics of humans and their pathogens. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Aebersold,et al.  Analysis, statistical validation and dissemination of large-scale proteomics datasets generated by tandem MS. , 2004, Drug discovery today.

[20]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[21]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[22]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[23]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[24]  Hans-Georg Rammensee,et al.  Cellular peptide composition governed by major histocompatibility complex class I molecules , 1990, Nature.

[25]  S. Nathenson,et al.  Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule , 1990, Nature.

[26]  H. Rammensee,et al.  Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. , 1990, Science.